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was 173.8  117.3 days, with no stroke or death, but there was 1 TIA
and 3 major bleeding.
CONCLUSIONS In our early Canadian experience, WATCHMAN for
LAA closure in patients contraindicated to anticoagulation is safe and
effective.
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BACKGROUND Percutaneous left atrial appendage (LAA) closure is
increasingly performed as an alternative to oral anticoagulation (OAC)
in patients with nonvalvular atrial ﬁbrillation (AF). We sought to
evaluate the cost-effectiveness of treating OAC contraindicated pa-
tients with the Amplatzer Cardiac Plug (ACP) device as compared to
aspirin alone.
METHODS A probabilistic patient-level Markov microsimulation
model with a lifetime horizon was performed to assess the discounted
lifetime costs, quality-adjusted life years (QALYs) and incremental
cost-effectiveness ratio of ACP compared to aspirin for AF patients
with contraindications to OAC. Baseline characteristics of the popu-
lation were based upon a published multi-center Canadian ACP
experience for patients at high stroke-risk (CHA2DS2-VASc) and OAC
contraindications. Clinical events included stroke, bleeding, myocar-
dial infarction, and procedure-related complications. Event-rates for
stroke and bleeding were based on the CHA2DS2-VASc and HASBLED
scores. The relative efﬁcacy of ACP and aspirin, as well as utility
scores, were obtained from the published literature. Canadian pro-
cedural and long-term costs were obtained from the Ontario Case
Costing Initiative and the Ontario Ministry of Health and Long Term
Care.
RESULTS Aspirin was less effective than LAA closure with ACP (4.26
 0.52 QALYs versus 4.69  0.33, respectively). The average dis-
counted lifetime cost was $30,830  11,726 for ACP and $39,751 
18,943 for aspirin. Thus, ACP was the dominant option, in that it was
both more effective and less expensive. Our results were robust with a
relatively modest degree of uncertainty, as ACP was the preferred
option in over 90% of simulations at a willingness-to-pay threshold of
$50,000 (ﬁgure).
CONCLUSIONS LAA closure is a novel stroke preventative therapy for
nonvalvular AF and is a cost-effective alternative to aspirin in patients
with contraindications to OAC.
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BACKGROUND Percutaneous left atrial appendage closure (LAAC) has
been although recognized as a new interventional routine, but the
clinical experience with large number of patients from single hospital
without cardiac surgery was worldwide very little. We evaluate pa-
tient selection, safety, feasibility, and midterm results of LAAC with
Watchman left atrial appendage (LAA) device in a single usual hos-
pital without onsite cardiac surgery backup.
METHODS A retrospective review of LAAC cases with Watchman
LAA device in our hospital between February 2012 and April 2015.
Demographic, echocardiographic, procedural, and clinical follow-up
data were collected and analyzed.
RESULTS LAAC was performed using Watchman device in 181 non-
valvular atrialﬁbrillation (NVAF)patientswith long-termoral anticoagulants
(OAC) contraindication. Mean age at closurewas 74.757.78 (range from 47-
92 years), 72.9% male. Hypertension, coronary artery disease, and diabetes
werepresent in71.9%,61.3%,and27.1%patients, respectively.MeanCHADS2
,CHA2DS-VASc and HASBLED scores were 2.21.1, 3.61.4 and 3.61.0,
respectively. Success rate of device implantation was 96.1% (93% in ﬁrst 90
cases, 99% in the second 91 cases) and associated with no major procedural
complications except one case of pericardial tamponade. Two Watchman
left atrial appendage devices were successful implanted in 3 cases due to
atypical anatomy of LAA. At least two transesophageal echocardiography
were performed in the ﬁrst 6 weeks and 6 months after LAAC, respectively.
Followupwas achieved in 92.5% patients and collected over amean follow-
up period of 266 days (range: 34 days to 3.0 years). No device related death
was recorded. At the most recent follow-up, almost all patients were
receiving antiplatelet therapy. Ischemic stroke/transient Ischemic attackwas
observed at an annual rate of 1.6% and the annual rate of any thromboem-
bolic (TE) event was 3.1%. Annual rate of major bleeding was 1.6%
CONCLUSIONS LAAC is a safe and effective stroke prevention therapy
in NVAF patients in a single usual hospital without onsite cardiac
surgery backup both at implantation and during short and midterm
follow-up periods and remarkable improvement of success rate can be
achieved with the increase of the experience of operators. A low
number of TE events was recorded during follow-up.
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BACKGROUND In left atrial appendage occlusion procedures, echo-
cardiography provides guidance for transseptal puncture, sizing and
device implantation and is utilized to assess occlusion grade. Most
cases of LAA closure are performed under general anesthesia and TEE
for guidance. ICE is used for guidance of interventional procedures,
however LAA visualization from the right atrium is often limited. The
aimof this studywas to assess the feasibility of LAAocclusion under ICE
guidance from the left atrium, conscious sedation and local anesthesia.
METHODS From October 2012 to June 2015, in one tertiary care center
in Montreal, 49 consecutive patients (mean age 758y) with AF and
long-term contraindication for anticoagulation underwent LAA
closure under local anesthesia, conscious sedation and ICE guidance
from the left atrium. The ICE catheter and device delivery sheaths
were advanced into the LA through separated ICE-guided transseptal
punctures. Baseline characteristics, procedural and follow-up data
were prospectively recorded. Procedural success was deﬁned as the
implantation of the closure device with adequate occlusion (grade 3
by angiography and<3 by ICE).
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5(IQR4-6) and 4(IQR4-5). In most patients (46/49), serious or repeated
bleeding was the procedural indication. Conscious sedation was ach-
ieved in all patients using midazolam 1.5mg (IQR1-2) and fentanyl
100mcg (IQR 75-150). Devices implanted included the Amplatzer
Cardiac PlugTM in 22, AmuletTM (St.Jude Medical Inc.) in 20 and
UltraSeptTM LAA Occluder (Cardia Inc, Eagen, MN) in 7. In all cases
ICE provided adequate LAA visualization, procedural guidance, oc-
clusion assessment, and device visualization and its relation with
adjacent structures. Procedural success was achieved in all but 1 pa-
tient (challenging anatomy and consequent failure to implant the
device). Median procedural time was 91min (IQR 81-119). Median
hospital stay was 1 day. There was no procedural stroke or device
embolization. Two patients developed tamponade, one treated with
pericardiocentesis and 1 required surgical repair. Two patients had
access site hematomas. No ICE related complication was noted. At 3
months 87% of patients had clinical and TEE follow-up. Non-clinically
signiﬁcant residual interatrial shunts were found in 7/42. Successful
LAA occlusion was observed in 41 of the 42 patients with follow-up
TEE; one patient had a 4 mm residual leak. Three patients died during
this period, all were non-procedure related deaths. Two patients had a
recurrent GI bleeding and were hospitalized for transfusions.
CONCLUSIONS This pilot experience suggests that LAA occlusion in
conscious patients under ICE guidance from the left atrium offers
comprehensive LAA visualization, complete and reliable procedural
guidance and outcomes are in line with those of the TEE-guided se-
ries. This technique stands as a valid alternative for general anes-
thesia and TEE guidance for percutaneous LAA occlusion.
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BACKGROUND Interventional left atrial appendage (LAA) occlusion
has been shown to be non-inferior to warfarin therapy. Thus, the
Watchman device (Boston Scientiﬁc, Marlborough, MA, USA) has
recently been approved by the FDA for clinical use as alternative to
warfarin in the United States. Therefore, a massive increase in per-
formed LAA occlusions can be expected worldwide. However, peri-
procedural stroke has been a major contributor to adverse events in
clinical trials. A similar problem was encountered in the ﬁeld of
transcatheter aortic valve replacement (TAVR). In TAVR, the use of a
cerebral protection device (Sentinel CPS, Claret Medical Inc., Santa
Rosa, CA, USA) has been proven to reduce cerebral lesions as assessed
with magnetic resonance imaging (MRI). We hypothesized, that the
less invasive procedure of LAA occlusion leads to embolization of
solid material, too and that the use of a cerebral protection system
might reduce adverse events in LAA occlusion and even reduce long-
term adverse effects of microemboli like cognitive deterioration.
METHODS In ﬁve consecutive patients treated with LAA occlusion in
our center the Sentinel CPS cerebral protection device was used. For
LAA occlusion, the Watchman device was used in two patients and
the Amulet (St. Jude Medical Inc., St. Paul, MN, USA) in three pa-
tients. The procedures were performed according to the instructions
for use. Presence of LAA thrombus was ruled out before the procedure
by transesophageal echocardiography in all patients, the ﬁlters placed
after the transeptal puncture. Throughout the procedure, unfractio-
nated heparin was administered to maintain an activated clotting
time > 250 seconds. After LAA occlusion the ﬁlters were removed and
their content underwent histologic examination.
RESULTS A total of 10 ﬁlters (one proximal and one distal ﬁlter for each
patient)were collected andunderwentHistopathologic analysis (CVPath
Institute Inc.). Debris was found in all patients (9/10 ﬁlters). Acute
thrombus was found in 3 patients (2 Watchman; 1 Amulet), organizing
thrombus in 4 patients (1 Watchman; 3 Amulet). One Amulet patient
showed endocardial tissue and one other platelets in theirﬁlters. None of
the ﬁlters included calciﬁcations or other foreign material. The maximal
diameter of the collected material was 0.68 (0.9) mm. No patient
showed neurological abnormalities after the procedure.
CONCLUSIONS As expected the procedure of LAA occlusion leads to
embolization of thrombus material, either preexisting or induced bythe procedure, in all patients. This ﬁnding strongly encourages further
investigations of the underlying mechanisms for embolization of
different types of material, as well as the clinical impact of micro-
emboli. A potential difference between different devices in throm-
bogenic potential as seen in our small series should also be addressed
in future investigations and might help to improve device design and
implantation techniques.
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BACKGROUND We have previously reported a less invasive off-pump
epicardial ventricular enhancement (LIVE) procedure, which involves
an open chest exposure with placement of an anchoring system in an
experimental heart failure animal model. This study aimed to evaluate
whether a novel hybrid transcatheter ventricular restoration (TCVR)
approach, with thoracoscopic assistance, can achieve similar results in
an ovinemodel of ischemic heart failure and LV anteroseptal aneurysm
METHODS Left ventricular (LV) anteroseptal scar was created by
percutaneous coil-occlusion of the mid-left anterior descending cor-
onary artery. Two months later, the scar was completely excluded via
placement of serial pairs of anchors in the right ventricular septum
and LV anterior epicardium through either open chest surgical
approach (n¼8) or minimal invasive hybrid TCVR approach (n¼5). LV
performance was evaluated before (baseline) and six weeks after de-
vice implantation by echocardiography.
RESULTS All animals survived with no device or procedure-related
complications. TCVR signiﬁcantly reduced LV end-systolic and end-
diastolic volumes and increased the ejection fraction while stroke
volume was preserved at 6 weeks follow-up; the apical rotation was
signiﬁcantly improved (4.3 1.3 vs. baseline 0.52.7; p¼0.03) and LV
twist was restored (8.563.45 vs. baseline 3.715.39⁰, p¼0.04). No
difference was shown between the two groups in volume reduction,
ejection fraction or LV twist improvement (Table).Change at 6 weeks FU
from pre-device TCVR (n[5) Surgical (n[8) p ValveLV end-diastolic
volume (ml)-2911 (32%) -1211 (18%) 0.09LV end-systolic
volume (ml)-288 (46%) -176 (36%) 0.62Stroke volume (ml) -18 410 0.33
Ejection fraction (%) 145 148 0.76
LV apical rotation () 3.812.67 1.832.18 0.21
LV twist () 4.863.74 3.092.01 0.37CONCLUSIONS Compared with a more invasive open-chest surgical
procedure, hybrid, thoracoscopically assisted TCVR can achieve
similar volume reduction and improvement in contractility of the LV
in an ovine model of ischemic cardiomyopathy with LV anteroseptal
infarction. It might be a safe, effective and less invasive alternative to
current open surgical therapies.
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